Bionano Genomics (BNGO) Cash from Financing Activities (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Cash from Financing Activities data on file, last reported at $657000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 93.97% year-over-year to $657000.0; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (down 26.66% YoY), and the FY2025 full-year result was $24.0 million, up 275.66% from the prior year.
• Cash from Financing Activities eased to $657000.0 in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $68.5 million in Q4 2023 to a low of -$21.6 million in Q1 2024.
• A 5-year average of $8.7 million and a median of $3.9 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 212214.29% in 2023 and slumped 245.46% in 2024, its largest moves.
• Tracing BNGO's Cash from Financing Activities over 5 years: stood at $146000.0 in 2022, then soared by 46806.85% to $68.5 million in 2023, then tumbled by 94.32% to $3.9 million in 2024, then slumped by 58.79% to $1.6 million in 2025, then tumbled by 59.01% to $657000.0 in 2026.
• Business Quant data shows BNGO's Cash from Financing Activities at $657000.0 in Q1 2026, $1.6 million in Q4 2025, and $10.1 million in Q3 2025.